GlassScriptPhysician profile
John R Krouse
NPI 1740210301
$3,066.02
in general payments reported to CMS, 2019-2025
29 companies · $989 in 2025
The $989 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $217 · 2020: $14.56 · 2021: $37.51 · 2023: $1,184 · 2024: $624 · 2025: $989.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,797.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,796.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $534.24 | 2023-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $453.27 | 2023-2025 | |
| Boston Scientific Corporation | $222.78 | 2023-2025 | Watchman Access System, Bodyguardian, Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $209.93 | 2021-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $192.07 | 2023-2025 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $165.71 | 2023-2025 | |
| Impulse Dynamics (USA) INC. | $161.20 | 2023 | Optimizer |
| Medtronic Vascular, INC. | $136.29 | 2019 | |
| Abbott Laboratories | $97.82 | 2019-2025 | Mitraclip, Assurity, Accent |
| Amgen INC. | $96.56 | 2024-2025 | Repatha, Repatha |
| Regeneron Healthcare Solutions, INC. | $95.11 | 2023-2025 | Evkeeza |
| Bridgebio Pharma, INC. | $83.26 | 2025 | Attruby |
| Novo Nordisk INC | $70.71 | 2025 | Ozempic, Rybelsus |
| Esperion Therapeutics, INC. | $65.65 | 2023-2025 | Nexletol |
| Alnylam Pharmaceuticals INC. | $57.97 | 2025 | Amvuttra |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $49.07 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $47.28 | 2020-2025 | Wainua |
| Janssen Pharmaceuticals, INC | $42.26 | 2019-2024 | Xarelto |
| Heartflow, INC. | $41.58 | 2023-2024 | Ffrct |
| Shockwave Medical, INC | $39.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.41 | 2023 | Jardiance |
| Pfizer INC. | $28.54 | 2023-2024 | |
| Lexicon Pharmaceuticals, INC. | $24.73 | 2024 | |
| Scpharmaceuticals INC. | $24.59 | 2025 | |
| Atricure, INC. | $22.36 | 2025 | Atriclip Laa Exclusion System |
| Abiomed | $21.83 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $21.14 | 2025 | Dojolvi |
| Biotronik INC. | $17.62 | 2023 | Edora 8 Dr-T, Biomonitor |
| Kiniksa Pharmaceuticals, LTD. | $14.04 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Krouse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.